Abstract
Although it has been known for some time that pro-inflammatory cytokines are an essential driver of synovial joint inflammation in osteoarthritis (OA), drugs [e.g. Anakinra, Tocilizumab, Tofacitinib, Adalibumab] that target the signal transduction pathways activated by these cytokines
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
